Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: gcrispin	3/15/2005 9:19:07 PM
	of 946

If you look at the distribution of cycles for ST3 and ST4 you see that a great many more patients received six cycles for ST 3. This seems odd in that the doublet is a more toxic regimen. True, there is longer survival by adding carbo, but the percentage of patients that received six cycles was quite high. A lower percentage of patients in ST 4 received six cycles. The question arises if the patients in ST 4 are more within the criteria of a PS 2. status. Certainly, Bianco suggested that the sicker patients did better on Xyotax.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next